IRHYTHM TECHNOLOGIES INC (IRTC)
US4500561067 - Common Stock
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating...
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and...
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating...
Tuesday 11/5 Insider Buying Report: CMCO, IRTC
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring...
iRhythm Technologies Announces Third Quarter 2024 Financial Results
iRhythm Technologies Announces Third Quarter 2024 Financial Results
SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating...
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting about 1 in 500 people and is one of the leading causes of sudden cardiac death...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring...
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024...
RSI Alert: iRhythm Technologies (IRTC) Now Oversold
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device...
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
New data shows iRhythm’s next-generation Zio monitor LTCM patch ECG device superior real-world performance compared to prior generation device. ...
Commit To Purchase iRhythm Technologies At $50, Earn 19.8% Annualized Using Options
Relative Strength Alert For iRhythm Technologies
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM) market
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use...